Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt Inc (ADTX) is a pioneering biotechnology company developing innovative solutions to reprogram immune responses, with applications in organ transplantation and autoimmune disorders. This dedicated news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and strategic partnerships.
Access authoritative reporting on ADTX's flagship programs including Adimune for transplant tolerance and AditxtScore diagnostic platforms. Track developments in Apoptotic DNA Immunotherapy (ADi) and other novel approaches to immune modulation. The curated news feed covers earnings reports, research collaborations, and product pipeline updates while adhering to financial disclosure standards.
Bookmark this page for consolidated access to press releases, clinical trial data disclosures, and expert analyses of ADTX's position in the competitive immunotherapy landscape. Stay informed about technological breakthroughs through verified updates from primary sources.
Aditxt, Inc. (NASDAQ: ADTX) announced an amendment to its Exclusive License Agreement with Stanford University, extending its license for AditxtScore™ technology. This amendment grants Aditxt worldwide exclusivity in utilizing the technology for various applications, including organ transplantation and disease detection. The technology aims to enhance treatment personalization and clinical monitoring. Notably, Aditxt has also established an Immune Monitoring Center in Richmond, VA, and secured necessary accreditations to advance its operations.
Aditxt (NASDAQ: ADTX) has signed a share exchange agreement to acquire AiPharma Global Holdings, enhancing its position in the infectious disease therapeutics market. The transaction consists of two phases: an initial acquisition of 9.5% of AiPharma for 4.8 million shares and $250,000, followed by a secondary closing for the remaining 90.5% for approximately 39.9 million shares and another $250,000. AiPharma holds exclusive rights to the antiviral drug Avigan, with regulatory approvals in several countries, but its recent Phase 3 trial did not achieve statistical significance.
Aditxt, a biotech company, has announced a non-binding letter of intent to acquire a firm specializing in Point-of-Care diagnostics. This acquisition aims to enhance AditxtScore’s portfolio with at-home COVID-19 rapid antigen test kits and other diagnostics. Key benefits include access to global manufacturing capabilities, a seasoned management team, and various growth opportunities in early disease detection. However, the acquisition's completion hinges on satisfactory due diligence and negotiations, with an exclusivity period until January 31, 2022. Aditxt has also provided a secured loan to the target company.
Aditxt, Inc. (Nasdaq: ADTX) has successfully closed its underwritten public offering of 16,575,000 units, comprising shares of common stock and warrants. The offering price was set at $1.05 per unit, yielding gross proceeds of $17,403,750 before deductions. Each warrant allows the purchase of one share at $1.15, expiring five years post-issuance. An over-allotment option permits the underwriter to buy an additional 2,486,250 shares or warrants. Dawson James Securities, Inc. managed the offering, with legal counsel provided by Sheppard Mullin and Schiff Hardin.
Aditxt, Inc. (NASDAQ: ADTX) has amended its agreement with AiPharma Global, extending the deadline for a definitive agreement from November 30, 2021, to December 16, 2021. The amendment also eliminates a $4 million termination fee and reduces AiPharma's borrowing capacity from $8.5 million to $8 million. A cash payment of $500,000 will be required at closing. CEO Amro Albanna expressed optimism about aligning opportunities with AiPharma for 2022, but noted that the agreement remains subject to due diligence and various approvals.
Aditxt, Inc. (NASDAQ: ADTX) has announced a public offering of 16,575,000 units, priced at $1.05 each, to raise approximately $17.4 million. The units consist of shares of common stock and warrants for additional shares at an exercise price of $1.15, expiring in five years. The underwriter, Dawson James Securities, has a 45-day option to purchase up to 2,486,250 additional units. This offering follows a previously filed shelf registration statement with the SEC. Closing is expected on December 3, 2021, pending customary conditions.
Aditxt, Inc. (NASDAQ: ADTX) has announced an underwritten public offering of common stock and warrants. Dawson James Securities, Inc. will serve as the sole book-running manager for this offering. The offering is made under an effective shelf registration statement filed with the SEC. A prospectus supplement will be filed with the SEC and available online. Aditxt focuses on technologies aimed at enhancing immune system health through monitoring and reprogramming.
Aditxt, Inc. (NASDAQ: ADTX) has introduced AditxtScore™ for assessing COVID-19 immune status, marking its deployment by the Johnson County Sheriff's Office, Kansas' largest law enforcement agency. This platform provides a personalized immune profile, quantifying individuals' immune responses to COVID-19 with precision. It helps guide vaccination decisions based on antibody levels. Company officials, including Co-founder Amro Albanna, highlight the significance of tailored immune monitoring for effective health management amidst the pandemic.
Aditxt, Inc. (NASDAQ: ADTX) announced a webinar scheduled for 2 PM ET today to discuss its recent announcements. CEO Amro Albanna will provide comprehensive information to both current and prospective investors. Participants can submit questions via email at aditxt@edisongroup.com. To join the webinar, attendees can click here or enter the link in their browser.
Aditxt, Inc. (NASDAQ: ADTX) announced that the Phase 3 PRESECO trial of Avigan®/Reeqonus™ for COVID-19 did not meet its primary endpoint of time to sustained clinical recovery. Ongoing data analysis is expected. Additionally, Aditxt is in the process of acquiring a subsidiary of AiPharma Global, which holds rights to the antiviral favipiravir. This acquisition aims to enhance Aditxt's portfolio in antiviral therapies to address infectious diseases. CEO Amro Albanna emphasized the importance of evaluating the trial outcomes in conjunction with AiPharma Global.
